Please select the option that best describes you:
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
Answer from: Medical Oncologist at Academic Institution
The phase 3 KEYNOTE-689 and the phase 3 NIVOPOSTOP. A key distinction is that KEYNOTE-689 incorporated both neoadjuvant and adjuvant immunotherapy, while NIVOPOSTOP restricted immunotherapy to the adjuvant phase and specifically targeted patients with high-risk features (+ margins and ECS) post-surg...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
ASCO 2025 had several interesting abstracts for head and neck cancers. The following abstracts could reshape the landscape of locally advanced head and neck squamous cell carcinoma by finally showing improvement in outcomes with PD-1 inhibitors in the curative setting. Hopefully, these trials mark t...
Answer from: Radiation Oncologist at Academic Institution
ASCO 2025 included several interesting presentations regarding the role ofimmunotherapy in the primary therapy of HNC, skin squamous, CCA, and NPC. While Immunotherapy has been established as first-line therapy in R/M HNC, its role in the primary therapy has not yet been clear.Phase III studies like...
Comments
Radiation Oncologist at West Virginia University
The KEYNOTE trial just published in the NEJM is es...
The KEYNOTE trial just published in the NEJM is es...